Subgrouping Patients with Advanced NSCLC for Tailored Treatment

Video

The panel discusses how patients with advanced NSCLC are sub-grouped in NSCLC and how to approach treatment for each group.

Sponsored in part by Regeneron. Content independently created by OncLive.

Related Videos
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Stephen V. Liu, MD
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
A panel of 5 experts on lung cancer
Related Content
Ken Takeshita, MD

Dato-DXd Does Not Elicit Significant OS Improvement in Previously Treated, Advanced NSCLC

May 28th 2024
Article
Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

May 23rd 2024
Podcast
FDA

FDA Grants Breakthrough Therapy Designation to NVL-655 for Pretreated ALK+ NSCLC

May 17th 2024
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC

FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC

May 16th 2024
Article
Lung Cancer | Image Credit: © Axel Kock - stock.adobe.com

When Lung Cancer Took One Lung and COVID Took the Other, a Chicago Police Captain Was Left With Only One Option for Survival

May 16th 2024
Article